Grants and Giving

Grants and Giving is sponsored by Alnylam. Alnylam's Grants and Giving Office supports innovative, high-quality initiatives that provide healthcare professionals and patients with evidence-based, clinically-relevant and performance-based education to improve patient health.

Grants And Giving | Alnylam The Alnylam Grants and Giving Office is committed to supporting innovative, high-quality initiatives that provide healthcare professionals and patients with evidence-based, clinically-relevant, and performance-based education and improve patient health.

We invite eligible organizations to apply for funding for initiatives that are aligned with our disease areas of interest: Transthyretin-mediated Amyloidosis (ATTR amyloidosis), Acute Hepatic Porphyria (AHP), and Primary Hyperoxaluria Type 1 (PH1). Projects should enable education, address unmet needs, elevate the standard of care, focus on ongoing research, or address other relevant community needs.

Please note that activities must be compliant with all applicable legal and regulatory requirements. Below, please find details of the process of applying for funding and the different types of requests available at Alnylam.

At this time, Alnylam supports the following funding types: Educational activities developed and executed by independent third parties to maintain, develop, or increase the knowledge, skills, and professional performance of an HCP For questions about Educational Grants (CME), please contact the Alnylam Grants and Giving Office at grants@alnylam.

com Educational Grants (Non-CME) Provided to a third party organization for development of an educational activity directed at providing scientific, clinical and medical information with the goal of improving patient care, or provision of a service to patients For questions about Educational Grants (non-CME), please contact the Alnylam Grants and Giving Office at grants@alnylam.

com Funding provided to support educational clinical programs within healthcare academic organizations For questions about Clinical Fellowships, please contact the Alnylam Grants and Giving Office at grants@alnylam.

com Activity or project undertaken by Alnylam and one or more external organization(s) that provides an opportunity for each party to contribute particular expertise or services For questions about Collaborations, please contact the Alnylam Grants and Giving Office at grants@alnylam.

com or your local Alnylam office Support to registered charitable organizations to advance science, healthcare, education, or other genuine charitable purposes For questions about charitable donations, please contact CSR@alnylam. com Initiatives, such as events or projects, aimed at educating patients, caregivers, scientists, or healthcare professionals where Alnylam receives a tangible benefit.

For questions about Sponsorships, please contact sponsorships@alnylam. com or your local Alnylam office Grants and Giving Office Process for Educational Grants Alnylam reviews external funding applications regularly, with educational grants considered through a formal, monthly process and sponsorships, charitable donations, and collaborations on a rolling basis.

Applicants should ensure that funding applications are submitted well in advance of when funding may be needed (with a minimum of 45 days). While Alnylam seeks to support the many requests we receive annually, not every request can be approved and some requests may be funded at a lower amount than what was requested.

Regardless of the outcome, Alnylam is committed to providing timely communications for each application and decisions will be shared upon completion of review. For any questions or concerns on the submission process and guidelines, please contact the Grants and Giving Office at grants@alnylam. com .

We request that submissions are made electronically through our funding portal which is in English. If you have difficulty submitting your application in English, please contact our Grants and Giving office at grants@alnylam. com for further guidance.

Funding request must be submitted at least 45 days prior to the start date of the activity or program Support may only be provided to eligible organizations or entities; individual recipients may not apply for nor receive funding Proof of tax status must be valid and government-issued. If a request is incomplete or more information is requested, our Grants and Giving Office will contact you and ask for further information.

Please try to respond with the missing information as timely as possible. CME and non-CME grant requests are reviewed by the Alnylam Grant Review Committee on a monthly basis (this includes applications by Patient Advocacy Organizations) All other types of funding are reviewed on a rolling basis.

Funding decisions will be communicated via an email from the electronic portal Funding requests are not considered final until the execution of a ‘Letter of Agreement’ with Alnylam.

(CME and non-CME Grants only) A reconciliation of grants must be completed within 90 days of the activity or program end date Any funds that are not used must be returned to Alnylam Failure to complete a reconciliation and/or return unused funds may jeopardize the review of future funding requests from the requesting party.

Funding provided to support educational clinical programs within healthcare academic organizations in a given area of interest. Alnylam is independent from the selection of the individual Fellow, and the educational institution requesting the funding must demonstrate that it has the infrastructure, expert faculty, curriculum, and ability to design and conduct a successful fellowship program.

Area of Educational Interest A Clinical Fellowship Grant is intended to support clinical fellowship programs that mentor and advance the training of physicians in the diagnosis, treatment, and research of Transthyretin (ATTR) Amyloidosis.

The program will foster multidisciplinary collaboration to improve early recognition, optimize treatment pathways, and accelerate the translation of emerging science into high-quality, patient-centered care. The US Clinical Fellowship Program for academic year 2027-2028 is closed and no longer accepting applications. Details on the US Clinical Fellowship Program for academic year 2028-2029 will be posted in spring of 2027.

Continuing Medical Education Grants (CME) These are educational activities developed and executed by independent third party organizations to maintain, develop, or increase the knowledge, skills, and professional performance that a healthcare professional uses to provide services for patients, the public, or the profession. A CME grant is an unsolicited funding request that may be accredited or non-accredited.

Alnylam may not receive any tangible business benefit. Transparency of Alnylam’s support is required and is not considered a tangible benefit. Examples might include a live program at a medical conference or an online educational session for CME credit.

Educational Grants (non-CME) This is funding that is provided in response to an unsolicited request from an eligible third-party organization that has independently applied for grant support for accredited or unaccredited medical education activities or education directed to HCPs, patient organizations, patients, or other members of the health care community. Alnylam may not receive any tangible business benefit.

Transparency of Alnylam’s support is required and is not considered a tangible benefit. Examples of a non-CME Educational Grant might include educational videos or newsletters.

Responses to Requests for Proposals Throughout the year, Alnylam will post Request for Proposals (RFP) to inform organizations and qualified medical education providers that we are interested in receiving requests for independent medical education activities pertinent to Alnylam’s areas of interest and aligned to specifications outlined in our RFPs.

The grantee is responsible for the design and execution of the initiative supported by the grant, including compliance with any regulatory requirements. Alnylam may not receive any tangible business benefit. Transparency of Alnylam’s support is required and is not considered a tangible benefit.

When Alnylam receives a tangible business benefit for an event, project or program aimed at educating patients, caregivers, scientists, or healthcare professionals, this is considered a sponsorship. Examples of sponsorship might include (but are not limited to): corporate memberships, patient advocacy conference support, advertising opportunities, exhibition booths or satellite symposium time slots.

A Collaboration is an activity or project undertaken by Alnylam alongside one or more external organization(s) that provides an opportunity for each party to contribute particular expertise or services or that will enable more effective and efficient delivery of a program or services than if each party were to work alone or separately.

This collaborative effort includes, but is not limited to, jointly developing and agreeing upon a set of common goals and direction, sharing the risks and responsibility for obtaining those goals, and working together to achieve those goals, using the expertise and resources of each Collaborator.

Alnylam may provide monetary or in kind support to charitable organizations to advance science, healthcare, education, or to further other charitable organization goals. Charitable Donations may be used for philanthropic initiatives or general purposes that support the overall mission of the organization, for example, providing funding after a natural disaster.

Alnylam may not receive any tangible business benefit for charitable funding. Transparency of Alnylam’s support is required and is not considered a tangible benefit.

Disease Areas Of Interest Transthyretin-mediated Amyloidosis (ATTR amyloidosis) Increase knowledge of ATTR amyloidosis including: The multisystem burden of disease in both hereditary* and wild-type patients, including extracardiac manifestations such as gastrointestinal, renal, musculoskeletal, and mixed phenotype in wild-type ATTR Early recognition and diagnosis of disease within various scenarios of a patient’s journey Diagnostic testing modalities including, clinical assessments, laboratory biomarkers, imaging, genetic testing, counseling and implications for broader family Evolution of disease management and treatment decision making in various clinical scenarios based on up-to-date evidence (including real world data) and clinical guidelines, including: Optimal evidence-based treatment selection and sequencing according to: mechanism of action (including the novel concepts in disease pathophysiology, such as TTR dissociation and cleavage pathways) clinical trial data including patient relevant outcomes biomarker and imaging data data in cardiac and extra-cardiac manifestations safety, adherence, and tolerance evolving concepts regarding progression and regression of disease based on various criteria including, but not limited to, biomarkers/imaging Real world clinical assessment of key markers of disease progression and treatment response Quality improvement and implementation of best practices within a multidisciplinary framework (including cardiology, neurology, gastroenterology, nephrology, etc) to improve both diagnosis and management, including use of published implementation science work *with focus on the predominant variant in geography where education is targeted, for example V122I in the United States.

Acute Hepatic Porphyria (AHP) Increase knowledge of AHP including: The multisystemic nature, chronicity and clinical presentation of the disease and the implications for multidisciplinary diagnosis and management Early recognition and diagnostic process, including ordering, interpreting, and evaluating biochemical and genetic tests for diagnosis Management and treatment of acute hepatic porphyria, including burden of disease and patient experience Primary Hyperoxaluria Type 1 (PH1) Increase knowledge of PH1 including: The utility of genetic testing in the diagnosis of kidney disease and subsequent impact on patient management and clinical outcomes Improve knowledge of clinical practice recommendations in PH1 diagnosis, management, treatments, and clinical outcomes Improve understanding of the prevalence of PH1 across various regions and ethnic groups.

Effective September 1, 2026, Sponsorship applications will no longer be submitted via the portal. Please direct all Sponsorship inquiries to sponsorships@alnylam. com You are now leaving Alnylam.

com The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Visit our social channels to learn more about the innovative work we are doing at Alnylam. You are now leaving Alnylam. com You will be directed to another Alnylam website that may contain information about specific treatment(s), news and more.

You are now leaving Alnylam. com